FDA On “Critical Path” To Secure Support For Drug Development Project
Executive Summary
FDA will be seeking congressional support for its "Critical Path" initiative, Acting Commissioner Lester Crawford, PhD, said April 15 at the Food & Drug Law Institute's annual conference in Washington, D.C
You may also be interested in...
FDA’s “Critical Path” includes proof-of-concept guidance
FDA will release guidance on new requirements for proof-of-concept studies by the end of the year, Acting Commissioner Lester Crawford says. The guidance will be rolled out as part of FDA's "Critical Path" initiative (1"The Pink Sheet" April 19, 2004, p. 3)...
FDA’s “Critical Path” includes proof-of-concept guidance
FDA will release guidance on new requirements for proof-of-concept studies by the end of the year, Acting Commissioner Lester Crawford says. The guidance will be rolled out as part of FDA's "Critical Path" initiative (1"The Pink Sheet" April 19, 2004, p. 3)...
FDA Drug Development Strategy Includes Initiating Meetings With Firms
FDA will seek legislation empowering the agency to initiate meetings with industry on drug development, Acting Commissioner Lester Crawford, PhD, said